During the last four decades, transplantation has developed from a highly experimental treatment to one that offers cure rates of up to 90 percent for patients with leukemia and lymphoma. This procedure, however, is not without risk.
One of these major risks is Graft -vs.-host disease (GVHD). GVHD symptoms can range from a mild rash to serious and life-threatening damage to the skin and internal organs. The condition occurs when transplanted immune cells from a donor react against the tissue of a transplant recipient.
Decades of research at Fred Hutch, MD Anderson and other leading cancer research centers, have led to new approaches that can lower the risk of GVHD and decrease its severity. Yet despite these advances, nearly 60 percent of transplant recipients still face GVHD. About 20 to 30 percent of these cases are serious enough to endanger survival or cause lasting disability.
Join us to hear from our esteemed panelists who are developing tools and novel strategies to prevent these devasting side effects.